Prescription Assistance for DOXIL^® (doxorubicin HCI liposome injection)

Individuals who have been prescribed DOXIL^® for an approved use may be eligible for the prescription assistance and affordability options below. Each option requires a specific set of eligibility requirements. Visit program-specific sites or contact independent foundations to learn more.

For assistance or questions on any of the below programs, please call the DOXILine^® at 1-800-609-1083, Monday - Friday, 8:00 AM - 8:00 PM ET.

Important Safety Information
Full Prescribing Information, Including Boxed WARNING

Doxil.com->

What type of insurance coverage do you have for DOXIL^®?

I have Private or Commercial coverage

I have Government (Medicare, Medicaid, TRICARE) coverage

I have Limited or No coverage

State-Sponsored Programs

Some states have State Pharmaceutical Assistance Programs (SPAPs) that help residents pay for their medications. Eligibility requirements differ from program to program, and may be based on financial need, age, medical condition, or current prescription coverage.

Find out more about SPAPs in your state

Am I Eligible?

Eligibility requirements vary for each state-sponsored program. Find out more about SPAPs in your state to see if you qualify.

Independent Foundations

The following independent foundations may be able to provide prescription assistance to qualified patients who are prescribed DOXIL^®. Visit the foundation web sites or contact the foundations directly for the most current information.

This list was last updated on June 3, 2013.

Johnson & Johnson Patient Assistance Foundation

Johnson & Johnson Patient Assistance Foundation, Inc. (JJPAF), is committed to helping you get the prescription medications you need. If you qualify, the Johnson & Johnson Patient Assistance Foundation, Inc., Patient Assistance Program makes it easier for you to receive free medications manufactured by the Operating Companies of Johnson & Johnson.

Phone: 1-800-652-6227

JJPAF.org

Am I Eligible?

This option may be right for you if you currently have very limited or no insurance coverage for DOXIL^®.

Chronic Disease Fund^®

Multiple Myeloma
Phone: 1-877-968-7233
E-mail: info@cdfund.org

Cdfund.org

Am I Eligible?

This option may be right for you if you currently have government insurance coverage (Medicare, Medicaid, TRICARE) or commercial or private health insurance coverage for DOXIL^®.

Patient Access Network Foundation

Multiple Myeloma
Phone: 1-866-316-PANF (1-866-316-7263)
E-mail: contact@patientaccessnetwork.org

Panfoundation.org

Patient Advocate Foundation

Multiple Myeloma
Phone: 1-866-512-3861

Copays.org

Please see Important Safety Information and Indications below.

INDICATIONS AND IMPORTANT SAFETY INFORMATION FOR DOXIL^® (doxorubicin HCl liposome injection)

IMPORTANT SAFETY INFORMATION

Serious and possibly permanent heart-related side effects that may lead to congestive heart failure can occur in patients treated with DOXIL^®. Inform your doctor of any history of heart disease, radiation to your chest, or prior anticancer therapy. Your doctor will monitor your heart function.

Infusion reactions may also occur during administration. Be sure to tell your doctor if you have any symptoms during infusion, including: flushing, shortness of breath, facial swelling, headaches, chills, back pain, tightness in your chest or throat, dizziness, or lightheadedness. For most patients, these reactions have resolved within several hours to a day once the infusion is stopped, or for some patients with slowing of the infusion rate. However, in some cases, these reactions may be serious and sometimes life-threatening and may be fatal.

DOXIL^® may severely reduce the number of blood cells (red blood cells, white blood cells, and cells that prevent bleeding called platelets) in your body that may potentially increase risk of infections, anemia, and bleeding. Speak to your doctor if you notice any changes in your health. Your doctor will monitor your blood laboratory results.

Talk to your doctor if you have a history of heart disease or liver disease, or have received prior radiation therapy and/or anticancer therapy.

If you are pregnant, planning to become pregnant, or nursing inform your doctor. Nursing should be discontinued during treatment with DOXIL^®.

You should not take DOXIL^® if you have a prior history of allergic reactions to doxorubicin or other ingredients found in the formulation. Please inform your doctor about your history of allergic reactions to medications or other substances.

Very rare cases of oral cancer have been reported in people who had taken DOXIL^® more than one year or who had taken a total dose greater than 720 mg/m². The oral cancer was diagnosed during treatment and up to 6 years after the last dose. Your doctor will examine you at regular times for the signs and symptoms of oral cancer.

The most common side effects reported in at least 20% of patients treated with DOXIL^® during clinical studies were: weakness, fever, nausea, vomiting, stomatitis (painful redness, swelling, or sores in the mouth), diarrhea, and rash, loss of appetite, low white blood cell count, low platelet count, anemia, tiredness, and constipation. Hand-foot syndrome, which may lead to tingling or burning, redness, flaking, bothersome swelling, small blisters, or small sores on palms of hands or soles of feet, was reported as well. In certain cases, this reaction can be more severe leading to serious infections, interfering with walking and other daily activities.

In the treatment of multiple myeloma, nerve damage called peripheral neuropathy, which may lead to pain, numbness, burning sensation, tingling, and more serious symptoms, was reported in >40% of patients.

Be sure to tell your doctor immediately if you experience any of these or other symptoms.

DOXIL^® may make the side effects of other anticancer therapies worse when used in combination.

Following administration, DOXIL^® may turn urine and other bodily fluids a reddish-orange color. This is due to the color of DOXIL^® and will go away as the drug leaves the body.

Your doctor may prescribe antinausea medications before or during your DOXIL^® treatment.

Please talk to your doctor or nurse if you have any additional questions regarding DOXIL^®.

For more information about DOXIL^® therapy, please visit www.DOXIL.com.

Please see full Product Information for more details.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088 (1-800-332-1088).

INDICATIONS

DOXIL^® (doxorubicin HCl liposome injection) is indicated for the treatment of patients with ovarian cancer whose disease has progressed or recurred after platinum-based chemotherapy.

DOXIL^® in combination with bortezomib is indicated for the treatment of patients with multiple myeloma who have not previously received bortezomib and have received at least one prior therapy.

DOXIL^® is administered intravenously by your healthcare professional.

K08D13018R2